ICER plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals, Inc.) and belimumab (BENLYSTA®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and belimumab is seeking a label expansion for the treatment of lupus nephritis; both are expecting FDA decisions in early 2021.

Date of review: March 2021

For questions, please contact Catherine Koola, Program Manager, at ckoola@icer.org.

Interventions of Interest:

  • voclosporin (Aurinia Pharmaceuticals, Inc.)
  • belimumab (BENLYSTA®, GlaxoSmithKline)

View the Key Stakeholders List.